Keywords: neurogen, oral, ra, drug, disappoints, usa-based, reported

Neurogen's oral RA drug disappoints

Article | 21 June 2004

Print This

USA-based Neurogen has reported that its oral C5a antagonist, NGD 2000-1, has failed to meet its main objectives in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in